Management of pseudomyxoma peritonei originating from the appendix: a single-center experience / 中国肿瘤临床
Chinese Journal of Clinical Oncology
;
(24): 460-464, 2020.
Article
in Chinese
| WPRIM
| ID: wpr-861598
ABSTRACT
Objective:
To analyze the clinical outcomes of pseudomyxoma peritonei(PMP) originating from the appendix following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).Methods:
A retrospective study was carried out by analyzing clinical data of patients who diagnosed with PMP originating from appendix and had undergone CRS and HIPEC between January 2012 and December 2018.Results:
A total of 604 patients had undergone 621 CRS and HIPEC procedures. The average age of the patients was 56.7 years. Of the patients, 364 (60.3%) were female and 240 (39.7%) were male. The median peritoneal carcinomatosis index (PCI) was 25.7. Of the patients, 28.5% (172/604) had undergone complete cytoreduction (CCR 0/1). In this study, the incidence of grade 3-4 adverse events was 21.7% (131/604), and the perioperative mortality rate was 0.7% (4/604). For the entire cohort, the 5-year survival rate was 53.6%. High-grade pathological subtype CCR 2/3, PCI >20, and grade 3-4 adverse events were independent predictors of a poor overall survival.Conclusions:
Appendix-derived PMP is rare, and its treatment should be considered carefully. For patients who are suspected or are confirmed as PMP, early standardized CRS and HIPEC are related to a better prognosis.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Observational study
/
Prognostic study
Language:
Chinese
Journal:
Chinese Journal of Clinical Oncology
Year:
2020
Type:
Article
Similar
MEDLINE
...
LILACS
LIS